<TEXT>&#2;<DATELINE>2005-08-12</DATELINE><TITLE>Cost-Benefit of Stockpiling Drugs for Influenza Pandemic</TITLE><BODY>We analyzed strategies for the use of stockpiled antiviral drugs in the context of a future influenza pandemic and estimated cost-benefit ratios. Current stockpiling of oseltamivir appears to be cost-saving to the economy under several treatment strategies, including therapeutic treatment of patients and postexposure prophylactic treatment of patients' close contacts.&#3;</BODY></TEXT>